Antioxidant Activity of 3-methyl-1-phenyl-2-pyrazolin-5-one
Overview
Biology
Endocrinology
Authors
Affiliations
The antioxidant activity of an anti-ischemic agent, 3-methyl-1-phenyl-2-pyrazolin-5-one (MCI-186), was examined. The pKa value of MCI-186 is 7.0 and the rate of oxidation of MCI-186 initiated with an azo compound increased with increasing pH, suggesting that the anionic form of MCI-186 is much more reactive than the non-ionic form. The major products were 3-methyl-1-phenyl-2-pyrazolin-4,5-dione (4,5-dione) and 2-oxo-3-(phenylhydrazono)-butanoic acid (OPB). Hydrolysis of 4,5-dione gave OPB. The minor intermediate product was 4-hydroxy-4-(3-methyl-1-phenyl-1H-pyrazolin-5-on-4-yl)-3-methyl-1-phenyl-1H-pyrazolin-5-one (BPOH). The nucleophilic attack of the anionic form of MCI-186 to 4,5-dione is likely to give BPOH. MCI-186 (50 μM) inhibited the aerobic oxidation at 37°C of 5.2 mM unilamellar soybean phosphatidylcholine (PC) liposomal membranes, initiated with a water-soluble initiator, as efficientlyas did ascorbate (100 μM). MCI-186 (50 μM) also inhibited the oxidation of the same PC liposomal membranes, this time initiated with a lipid-soluble initiator, almost as efficiently as did α-tocopherol (2 μM). Furthermore, the combination of MCI-186 with ascorbate or α-tocopherol showed almost complete inhibition of PC oxidation induced by both initiators. These data suggest that MCI-186 may work as a good antioxidant in cellular systems as well as in cell-free systems.
Cao R, Song C, Wang Z, Lv B, Xiao W, Chen G Mol Divers. 2025; .
PMID: 39847187 DOI: 10.1007/s11030-024-11054-w.
Ansari U, Alam M, Nadora D, Muttalib Z, Chen V, Taguinod I AIMS Neurosci. 2024; 11(2):166-177.
PMID: 38988889 PMC: 11230861. DOI: 10.3934/Neuroscience.2024010.
Current perspectives on neuromodulation in ALS patients: A systematic review and meta-analysis.
Jimenez-Garcia A, Bonnel G, Alvarez-Mota A, Arias N PLoS One. 2024; 19(3):e0300671.
PMID: 38551974 PMC: 10980254. DOI: 10.1371/journal.pone.0300671.
Update on Antioxidant Therapy with Edaravone: Expanding Applications in Neurodegenerative Diseases.
Yamashita T, Abe K Int J Mol Sci. 2024; 25(5).
PMID: 38474192 PMC: 10932469. DOI: 10.3390/ijms25052945.
Edaravone: A Novel Possible Drug for Cancer Treatment?.
Duranti E, Cordani N, Villa C Int J Mol Sci. 2024; 25(3).
PMID: 38338912 PMC: 10855093. DOI: 10.3390/ijms25031633.